Moreover, additional tyrosine kinase inhibitors, such as sunitinib, and AKT inhibitors could be a useful HLRCC therapy in the context of PTEN inhibition [89]. The gene discussed is PTEN; the disease is hereditary leiomyomatosis and renal cell cancer.